Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Argiris Symeonidis

Showing results (81-90 of 138) with videos related to

Pageof 14
Sort By:
European Journal of Haematology|July 5, 2017
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapiesFlora Zagouri, Efstathios Kastritis, Athanasios Zomas, et al.
Annals of Hematology|July 30, 2013
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study GroupEirini Katodritou, Chrysanthi Vadikolia, Chrysavgi Lalagianni, et al.
Ejhaem|July 18, 2022
Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort studyKonstantinos Liapis, Georgios Vrachiolias, Vasileios Papadopoulos, et al.
Leukemia & Lymphoma|November 15, 2018
Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification systemPanagiotis T Diamantopoulos, Ioannis Kotsianidis, Argiris Symeonidis, et al.
Haematologica|April 10, 2025
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS RegistryBente Houtman, Adele Taylor, Corine Van Marrewijk, et al.
British Journal of Haematology|February 18, 2026
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategiesAleksandar Savic, Adele Taylor, Pierre Fenaux, et al.
The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Medicina (Kaunas, Lithuania)|May 25, 2024
A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and <i>CTLA4</i>-Mediated Immune Dysregulation Syndrome in GreeceAndroniki Kapousouzi, Fani Kalala, Styliani Sarrou, et al.
Leukemia|May 24, 2019
A revised international prognostic score system for Waldenström's macroglobulinemiaEfstathios Kastritis, Pierre Morel, Alain Duhamel, et al.
European Journal of Haematology|January 13, 2026
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data AnalysisNoemi Puig, Xavier Leleu, Hans C Lee, et al.
Pageof 14

Showing results (81-90 of 138) with videos related to

Sort By:
Pageof 14
European Journal of Haematology|July 5, 2017
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapiesFlora Zagouri, Efstathios Kastritis, Athanasios Zomas, et al.
Annals of Hematology|July 30, 2013
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study GroupEirini Katodritou, Chrysanthi Vadikolia, Chrysavgi Lalagianni, et al.
Ejhaem|July 18, 2022
Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort studyKonstantinos Liapis, Georgios Vrachiolias, Vasileios Papadopoulos, et al.
Leukemia & Lymphoma|November 15, 2018
Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification systemPanagiotis T Diamantopoulos, Ioannis Kotsianidis, Argiris Symeonidis, et al.
Haematologica|April 10, 2025
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS RegistryBente Houtman, Adele Taylor, Corine Van Marrewijk, et al.
British Journal of Haematology|February 18, 2026
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategiesAleksandar Savic, Adele Taylor, Pierre Fenaux, et al.
The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Medicina (Kaunas, Lithuania)|May 25, 2024
A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and <i>CTLA4</i>-Mediated Immune Dysregulation Syndrome in GreeceAndroniki Kapousouzi, Fani Kalala, Styliani Sarrou, et al.
Leukemia|May 24, 2019
A revised international prognostic score system for Waldenström's macroglobulinemiaEfstathios Kastritis, Pierre Morel, Alain Duhamel, et al.
European Journal of Haematology|January 13, 2026
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data AnalysisNoemi Puig, Xavier Leleu, Hans C Lee, et al.
Pageof 14